Actively Recruiting
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
Led by Ain Shams University · Updated on 2025-07-28
118
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis. Objectives : 1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring: * Serum Sirtuin 1(SIRT1) * Serum Myeloperoxidase (MPO) * Serum C-reactive protein (CRP) 2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score). 3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI). 4. To assess any adverse effects related to Resveratrol. Patients: Eligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups: 1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months. 2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.
CONDITIONS
Official Title
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients older than 18 years
- Diagnosis of rheumatoid arthritis according to ACR/EULAR 2010 criteria
- Moderate to high disease activity with DAS-28-CRP score greater than 3.2
- Receiving a stable regimen of one or more conventional synthetic DMARDs for at least 3 months
- Rheumatoid arthritis patients with moderate or high disease activity (DAS-28-CRP >3.2)
You will not qualify if you...
- Receiving biologic DMARDs therapy for rheumatoid arthritis
- Taking any other anti-inflammatory drugs
- Taking any other antioxidants
- Pregnant or lactating women
- Other rheumatological or inflammatory diseases or malignancies
- Smokers
- Thyroid illnesses
- Impaired liver function with liver transaminases three times above the upper normal limit
- Impaired kidney function with estimated glomerular filtration rate less than 30 ml/min
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Rheumatology at Ain Shams university hospital, Cairo, Egypt
Cairo, Egypt
Actively Recruiting
Research Team
R
Rana El-Dash, MsC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here